Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

Kilian, Adam; Chock, Yu Pei Eugenia; Huang, Irvin J.; Graef, Elizabeth R.; Upton, Laura; Khilnani, Aneka; Krupnikova, Sonia D. Silinsky; Almaghlouth, Ibrahim; Cappelli, Laura C.; Fernández-Ruiz, Ruth; Frankel, Brittany A.; Frankovich, Jourdan; Harrison, Carly; Kumar, Bharat; Monga, Kanika; Vega, Jorge A. Rosario; Singh, Namrata; Sparks, Jeffrey A.; Sullo, Elaine; Young, Kristen J.; Duarte‐García, Alí; Putman, Michael; Johnson, Sindhu R.; Grainger, Rebecca; Wallace, Zachary S; Liew, David; Jayatilleke, Arundathi

doi:10.1016/j.semarthrit.2020.07.007

Cited by 21 publications

(28 citation statements)

References 173 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reports underlined the magnitude of a cytokine storm in adults, patients receiving immunomodulatory treatment for either auto-inflammatory diseases, or autoimmune diseases received peculiar attention. Finally, until now, there have been no reports of concern for these patients and they did not show a higher risk for developing either COVID19 or its severe forms (10)(11)(12).…”

Section: Introductionmentioning

confidence: 85%

See 1 more Smart Citation

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

2020

View full text Add to dashboard Cite

Globally, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared to have a milder clinical course in children compared to adults. As severe forms of COVID-19 in adults included an aberrant systemic immune response, children with chronic systemic inflammatory diseases were cautiously followed. No evidence for a specific susceptibility was identified in this pediatric population. European and US Pediatricians started to notice cases of myocarditis, sharing some features with toxic shock syndrome, Kawasaki disease, and macrophage activation syndrome in otherwise healthy patients. Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric Inflammatory Multisystem Syndrome (PIMS) have designated this new entity in the US and Europe, respectively. The spectrum of severity ranged from standard hospitalization to pediatric intensive care unit management. Most patients had a clinical history of exposure to COVID-19 patients and/or SARS-COV2 biological diagnosis. Clinical presentations include fever, cardiac involvement, gastro-intestinal symptoms, mucocutaneous manifestations, hematological features, or other organ dysfunctions. The temporal association between the pandemic peaks and outbreaks of PIMS seems to be in favor of a post-infectious, immune-mediated mechanism. Thus, SARS-CoV2 can rarely be associated with severe systemic inflammatory manifestations in previously healthy children differently from adults highlighting the specific need for COVID-19 research in the pediatric population.

show abstract

Section: Introductionmentioning

confidence: 85%

“…On the other hand, outbreaks of chilblain-like lesions have been described in adolescents weeks after symptoms compatible with COVID19 (12)(13)(14). In the study by Landa et al they described six patients with chilblain-like lesions, mostly without other coronavirus symptoms.…”

Section: Ifn Type I Response May Have a Critical Rolementioning

confidence: 99%

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

2020

View full text Add to dashboard Cite

show abstract

“…2,[152][153][154] Multiple studies to date have reported significantly increased risk of serious infections in patients on sGC, with doses as low as 10 mg prednisone-equivalent, although this mostly corresponds to bacterial infections. 28,[155][156][157][158][159][160] Hydroxychloroquine (HCQ) use is recommended in most patients with SLE, owing to multiple health benefits in patients with SLE and overall safety. [161][162][163][164] Various observational studies have indicated a protective effect of HCQ against serious infections in SLE.…”

Section: Commonly Used Drugs In Sle and Predisposition To Viral Infecmentioning

confidence: 99%

“…175 Furthermore, a recent review did not find sufficient evidence to conclude that AZA, MMF, or CYC increased the risk of acute respiratory viral adverse events in patients with SLE or other rheumatic diseases. 156 Tacrolimus, a calcineurin inhibitor used as a single agent or in combination with MMF in SLE, has been associated with a relatively low incidence of severe infections in various reports, although data are scarce. 156,176,177 A comparison between SLE patients on sGC and tacrolimus vD 1 4 5 X Xs those on sGC and CYC showed a similar incidence rate of herpes zoster and varicella between the D 1 4 6 X X2 groups.…”

Section: Commonly Used Drugs In Sle and Predisposition To Viral Infecmentioning

confidence: 99%

“…156 Tacrolimus, a calcineurin inhibitor used as a single agent or in combination with MMF in SLE, has been associated with a relatively low incidence of severe infections in various reports, although data are scarce. 156,176,177 A comparison between SLE patients on sGC and tacrolimus vD 1 4 5 X Xs those on sGC and CYC showed a similar incidence rate of herpes zoster and varicella between the D 1 4 6 X X2 groups. 178 Belimumab, a B lymphocyte stimulator D 1 4 7 X Xinhibitor, is currently the only biologic approved for use in SLE.…”

Section: Commonly Used Drugs In Sle and Predisposition To Viral Infecmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Fernández-Ruiz

Paredes

Niewold

2021

Translational Research

Self Cite

View full text Add to dashboard Cite

As the world navigates the Coronavirus disease 2019 (COVID-19) pandemic, there is a growing need to assess its impact in patients with autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). Patients with SLE are a unique population when considering the risk of contracting COVID-19 and infection outcomes. The use of systemic glucocorticoids and immunosuppressants, and underlying organ damage from SLE are potential susceptibility factors. Most patients with SLE have evidence of high type I IFN activity, which may theoretically act as an antiviral line of defense or contribute to the development of a deleterious hyperinflammatory response in COVID-19. Other immunopathogenic mechanisms of SLE may overlap with those described in COVID-19, and thus studies in SLE could provide some insight into immune responses occurring in severe cases of the viral infection. We reviewed the literature to date on COVID-19 in patients with SLE and provide an in-depth review of current research in the area, including immune pathway activation, epidemiology, clinical features, outcomes, and the psychosocial impact of the pandemic in those with autoimmune disease.

show abstract

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Izadi¹,

Brenner²,

Mahil³

et al. 2021

JAMA Netw Open

Self Cite

100

View full text Add to dashboard Cite

IMPORTANCEAlthough tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. OBJECTIVE To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. DESIGN, SETTING, AND PARTICIPANTS This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age Ն18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included.EXPOSURES Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. MAIN OUTCOMES AND MEASURESThe main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations.RESULTS A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age (continued)

show abstract

Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

Cited by 21 publications

References 173 publications

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Contact Info

Product

Resources

About